Silence Therapeutics Plc American Depository Share
SLN
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Last trade$19.80
Day change-$0.005 (-0.03%)
Day range$19.76 – $19.90
Volume964,865
Market cap$1.23B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for SLN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for SLN.
Recent news
Company coverage with links to the original publishers.
Silence Therapeutics PLC (SLN) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate has increased 5.7% over the past three months, positioning it in the top 20% of Zacks-covered stocks for estimate revisions. The upgrade reflects improving business fundamentals that could drive near-term stock price appreciation.
The polycythemia vera market is expected to expand significantly by 2036, growing at 8.9% CAGR from a 2025 valuation of approximately USD 2 billion. Nine major pharmaceutical companies are advancing next-generation therapies in various clinical development stages, with rusfertide from Protagonist Therapeutics and Takeda expected to be the first new entrant to market this year, potentially reshaping the treatment paradigm beyond current standard therapies like JAKAFI, BESREMi, and PEGASYS.
The Australia ARDS market is projected to grow from USD 24.82 million in 2024 to USD 44.79 million by 2033, driven by rising respiratory diseases, technological innovations, and post-COVID lung damage awareness.
BESREMi, a FDA-approved treatment for polycythemia vera, is gaining market share due to its potential for better tolerability and lower risk of treatment-related malignancies compared to competitors like ruxolitinib and hydroxyurea.
The global RNA-based therapeutic market is expected to grow from $9.46 billion in 2025 to $40.81 billion by 2034, driven by the rising prevalence of genetic disorders and the demand for personalized medicine. North America and Asia Pacific are the key regional markets.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.